保加利亚索非亚，中国山东省 [2026年5月27日]
全球领先的动物保健与营养解决方案提供商浩卫制药与专注于球虫病疫苗生产的中国企业齐鲁青大，
今日宣布建立战略合作伙伴关系，共同开发和商业化创新的球虫病疫苗。
动物健康战略联盟
浩卫制药总裁 Kiril Domuschiev
此次合作将使浩卫制药能够借助齐鲁青大在疫苗生产方面的专长及其在中国市场的强大影响力，来
扩充其球虫病防控产品组合。齐鲁青大也将获得浩卫制药的研发、技术和市场营销资源，以及互补
性的产品组合，从而更好地服务于中国核心养殖客户。
推动畜牧业创新
浩卫制药中国区总经理江礼议（Johnny Chiang）表示："此次合作标志着我们在中国发展战略和
业务布局迈出了重要一步。
齐鲁青大的专长与我们现有的球虫病解决方案形成了完美互补。我们将共同提升疫苗质量，为中
国关键客户提供定制化服务，并开发新工具以应对畜牧业不断演变的挑战。"
齐鲁青大总经理 张学志补充道："我们与浩卫制药的合作将増强我们为核心客户提供的服务内容和
产品系列。这也将为研发开辟新途径，并使我们能够借助浩卫制药的全球网络和在家禽生产领域的
专业知识，来更好的服务于全球客户。
关于浩卫制药（Huvepharma）
浩卫制药是一家快速发展的全球性制药公司，专注于人类和动物健康及营养产品的研发、生产和销
售。以其在发酵和生产方面的专业知识而闻名，已成为全球十大兽药公司之一。浩卫制药总部位于
保加利亚索非亚，通过其位于保加利亚佩什泰拉的生产厂子公司Biovet为全球客户提供服务，并在
多个地点设有独立的生产基地。
公司拥有现代化的发酵、纯化和研发设施，能够生产主要药品原料和高质量的成品。凭借遍布全球
的销售办事处、子公司和当地代表组成的广泛商业网络，浩卫制药(Huvepharma)团队随时准备为客
户提供专业的支持。
关于齐鲁青大
齐鲁青大成立于2014年，是一家集研发、生产与销售鸡球虫病活疫苗为一体的国家科技型高新技术企
业。独有的保种技术，保证产品的效果稳定性，强大的研发技术能力不仅让公司的鸡球虫病活疫苗，
具有免疫保护力强、肠道副反应轻、以及改善综合料比的特点，更获得国内多家大型养殖集团的高度
认可。经过多年的市场验证和沉淀，齐鲁青大已发展成为国内球虫疫苗的主要生产厂之一，更进一
步致力于成为国际化、专业化球虫疫苗制造商。
本次交易，由西尧投资有限公司为浩卫制药提供服务。
关于西尧投资有限公司
专注于提供战略咨询及投资银行服务，业务严格聚焦于亚洲地区（尤其是大中华区与日本）的农业
综合企业、相关生命科学领域（包括动物保健与动物营养）、食品饮料生产及分销的全产业链。
Huvepharma and Qilu Tsingta Partner Joint Venture
“Huvepharma Tsingta Biopharmaceutical (Shandong) Co., Ltd.” to Advance Coccidiosis
Vaccines in China and Globally.
Sofia, Bulgaria and Shandong Province, China – [27 May 2026]
Huvepharma, a leading global provider of animal health and nutrition solutions, and Qilu
Tsingta,a Chinese specialist in coccidiosis vaccine production, today announced a strategic
partnership for the development and commercialization of innovative coccidiosis vaccines.
A Strategic Alliance for Animal Health
This collaboration will enable Huvepharma to expand its coccidiosis control portfolio by
leveraging Qilu Tsingta’s expertise in vaccine production and its strong presence in the
Chinese market. Qilu Tsingta will gain access to Huvepharma’s R&D, technical, and marketing
resources,as well as a complementary product portfolio, to better serve key livestock accounts
in China.
Driving Innovation for the Livestock Industry
Mr. Johnny Chiang, Managing Director Huvepharma China, stated: “This partnership marks a
significant step in our growth strategy and presence in China. Qilu Tsingta’s expertise perfectly
complements our existing coccidiosis solutions. Together, we will enhance vaccinequality,
deliver tailored services to key Chinese customers, and develop new tools to address the
evolving challenges of the livestock industry.”
Mr Xuezhi Zhang Managing Director Qilu Tsingta added: “Our partnership with Huvepharma
will strengthen our service offerings andproduct range for key clients. It will also open new
avenues for R&D and allow us to leverage Huvepharma’s global network and expertise in
poultry production, to better serve global customers.”
About Huvepharma
Huvepharma is a fast-growing global pharmaceutical and nutrition company focused on the
development,manufacturing, and marketingof human and animal health and nutrition
products. Well-known for its expertise in fermentation and production, Huvepharma has
established itself as one of the top ten veterinary pharmaceuticalcompanies worldwide.
Headquartered in Sofia, Bulgaria, Huvepharma serves customers all over the world,
operating through its manufacturing subsidiary, Biovet, based in Peshtera, Bulgaria, with
independentproduction units in multiple locations. The company’s modern fermentation,
purification, and R&D facilities enable the production of major molecules and high-quality
finished products. With an extensive global commercial network of sales offices, subsidiaries
and localrepresentatives in most countries, there is always a member of the Huvepharma
teamready to provide expert support.
About Qilu Tsingta
Qilu Tsingta founded in 2014, is a National High-Tech Enterprise specializing in the research
& development, production,and sales of live coccidiosis vaccines for chickens. The unique
preservation technology of master strains ensures the stability of product efficacy. The strong
R&D capabilitieshave not only enabled its live coccidiosis vaccines for chickens tohave strong
immune protection, mild intestinal side effects, and improved overall feed conversion ratio,
but have also gained high recognition from many large-scale poultry producers in China.
After years of market validation and development, Qilu Tsingta has become one of the
major manufacturers of coccidiosis vaccines in China and is further committed to becoming
a global coccidiosis vaccine Innovator.
Huvepharma was advised throughout the transaction by Shiyao Investment Ltd.
About Shiyao Investment Ltd
provides strategic advisory and investment banking services with a strict focus on the complete
supply chain of agribusiness,related life sciences(including animal health and animal nutrition) ,
food and beverage production and distribution in Asia, in particular Greater China and Japan.